270 related articles for article (PubMed ID: 29483082)
1. Inhibition of the IRE-1α/XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice.
Schutt SD; Wu Y; Tang CH; Bastian D; Nguyen H; Sofi MH; Zhang M; Liu C; Helke K; Wilson C; Schnapp LM; Del Valle JR; Hu CC; Yu XZ
Blood Adv; 2018 Feb; 2(4):414-427. PubMed ID: 29483082
[TBL] [Abstract][Full Text] [Related]
2. XBP-1s Promotes B Cell Pathogenicity in Chronic GVHD by Restraining the Activity of Regulated IRE-1α-Dependent Decay.
Choi HJ; Tang CA; Tian L; Wu Y; Sofi MH; Ticer T; Schutt SD; Hu CA; Yu XZ
Front Immunol; 2021; 12():705484. PubMed ID: 34659198
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.
Betts BC; Locke FL; Sagatys EM; Pidala J; Walton K; Menges M; Reff J; Saha A; Djeu JY; Kiluk JV; Lee MC; Kim J; Kang CW; Tang CH; Frieling J; Lynch CC; List A; Rodriguez PC; Blazar BR; Conejo-Garcia JR; Del Valle JR; Hu CC; Anasetti C
Front Immunol; 2018; 9():2887. PubMed ID: 30574153
[TBL] [Abstract][Full Text] [Related]
4. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.
Daenthanasanmak A; Iamsawat S; Chakraborty P; Nguyen HD; Bastian D; Liu C; Mehrotra S; Yu XZ
Blood; 2019 Jan; 133(3):266-279. PubMed ID: 30514750
[TBL] [Abstract][Full Text] [Related]
5. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Yao Y; Wang L; Zhou J; Zhang X
J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-31 regulates T-cell metabolism via HIF1α and promotes chronic GVHD pathogenesis in mice.
Wu Y; Mealer C; Schutt S; Wilson CL; Bastian D; Sofi MH; Zhang M; Luo Z; Choi HJ; Yang K; Tian L; Nguyen H; Helke K; Schnapp LM; Wang H; Yu XZ
Blood Adv; 2022 May; 6(10):3036-3052. PubMed ID: 35073581
[TBL] [Abstract][Full Text] [Related]
7. Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects.
Johnston HF; Xu Y; Racine JJ; Cassady K; Ni X; Wu T; Chan A; Forman S; Zeng D
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1089-103. PubMed ID: 24796279
[TBL] [Abstract][Full Text] [Related]
8. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
[TBL] [Abstract][Full Text] [Related]
9. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
10. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
[TBL] [Abstract][Full Text] [Related]
12. Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect.
Ilan Y; Margalit M; Ohana M; Gotsman I; Rabbani E; Engelhardt D; Nagler A
Hum Immunol; 2005 Mar; 66(3):231-40. PubMed ID: 15784461
[TBL] [Abstract][Full Text] [Related]
13. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
14. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.
Tang CH; Ranatunga S; Kriss CL; Cubitt CL; Tao J; Pinilla-Ibarz JA; Del Valle JR; Hu CC
J Clin Invest; 2014 Jun; 124(6):2585-98. PubMed ID: 24812669
[TBL] [Abstract][Full Text] [Related]
16. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
17. During acute graft versus host disease CD28 deletion in donor CD8
Uri A; Lühder F; Kerkau T; Beyersdorf N
Eur J Immunol; 2018 Dec; 48(12):2055-2067. PubMed ID: 30320878
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice.
Wu Y; Schutt S; Paz K; Zhang M; Flynn RP; Bastian D; Sofi MH; Nguyen H; Dai M; Liu C; Chang YJ; Blazar BR; Yu XZ
Blood; 2018 Apr; 131(17):1974-1986. PubMed ID: 29530952
[TBL] [Abstract][Full Text] [Related]
19. Activation of TREM-1 induces endoplasmic reticulum stress through IRE-1α/XBP-1s pathway in murine macrophages.
Dong L; Tan CW; Feng PJ; Liu FB; Liu DX; Zhou JJ; Chen Y; Yang XX; Zhu YH; Zhu ZQ
Mol Immunol; 2021 Jul; 135():294-303. PubMed ID: 33957479
[TBL] [Abstract][Full Text] [Related]
20. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
